{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:34:38Z","timestamp":1757705678508,"version":"3.37.3"},"reference-count":19,"publisher":"BMJ","issue":"3","funder":[{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"crossref","award":["PJT 156256"],"award-info":[{"award-number":["PJT 156256"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ EBM"],"accepted":{"date-parts":[[2022,12,11]]},"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To examine the association between regulatory reviewer disagreements and postmarket safety actions among novel therapeutics approved by the US Food and Drug Administration (FDA) between 2011 and 2015. Disagreements among FDA reviewers regarding the recommendation for a novel therapeutic\u2019s approval, its safety, the indicated patient population and\/or other parameters of the drug\u2019s approval are common. However, the implications of such disagreements\u2014particularly with respect to postmarket safety actions\u2014are poorly understood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Cross-sectional study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>All novel therapeutics approved by the FDA between January 2011 and December 2015.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>None.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measures<\/jats:title><jats:p>Postmarket safety actions defined as new label warnings\/increased warning severity, FDA safety communications and safety-related therapeutic withdrawals after the original regulatory approval.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 174 novel therapeutics approved by the FDA between 2011 and 2015, 42 (24%) had at least one regulatory reviewer disagreement. Altogether, 156 instances of disagreement were observed. Following market approval, a total of 253 postmarket safety actions were taken by the FDA among all new therapeutics, with at least one postmarket safety action identified for 98 (56.3%) of the 174 novel therapeutic approvals. Overall, therapeutics that were the subject of disagreement during the FDA\u2019s review had fewer safety actions following approval compared with therapeutics in which no disagreement was observed (38.1% vs 62.1%; RR 0.61, 95%\u2009CI 0.41 to 0.92; p=0.006). Therapeutic approvals containing at least one reviewer disagreement also more often carried a black box warning at the point of approval (47.7% vs 31.1%; RR 1.53, 95%\u2009CI 1.02 to 2.30; p=0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This investigation of regulatory reviewer disagreements and postmarket safety actions among new therapeutics suggests that disagreements among regulatory reviewers may lead to important pre-emptive actions, potentially mitigating the need for postmarket safety actions to be taken.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjebm-2022-112005","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T17:21:35Z","timestamp":1679419295000},"page":"151-156","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeutics"],"prefix":"10.1136","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9576-6989","authenticated-orcid":false,"given":"Ashley","family":"Eadie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"MacGregor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Wallach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-3320","authenticated-orcid":false,"given":"Joseph","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Herder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"2024052111014172000_28.3.151.1","unstructured":"Guidance for industry expedited programs for serious conditions-drugs and biologics guidance for industry. 2014. Available: http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htmand\/orhttp:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm [Accessed 16 Oct 2022]."},{"key":"2024052111014172000_28.3.151.2","unstructured":"21 U.S.C. \u00a7 355. title 21: food and drugs, chapter 9\u2014federal food, drug, and cosmetic act subchapter V, drugs and devices part A, drugs and devices sec. 355, new drugs. enacted. 2011. Available: https:\/\/www.govinfo.gov\/app\/details\/U [Accessed 17 Jun 2020]."},{"key":"2024052111014172000_28.3.151.3","unstructured":"Food and drug administration amendments act of 2007, 21 USC \u00a7355(l);"},{"key":"2024052111014172000_28.3.151.4","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jamainternmed.2020.1978","article-title":"Integrated drug reviews at the US food and drug administration-reply","volume":"180","author":"Doshi","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2024052111014172000_28.3.151.5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.9498","article-title":"Disagreements within the US food and drug administration regarding approval of novel therapeutic agents, 2011-2015","volume":"3","author":"MacGregor","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2024052111014172000_28.3.151.6","article-title":"Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries","volume":"45","author":"Dur\u00e1n","year":"2021","journal-title":"Rev Panam Salud Publica"},{"key":"2024052111014172000_28.3.151.7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254585","article-title":"Potential negative impact of reputed regulators\u2019 decisions on the approval status of new cancer drugs in Latin American countries: a descriptive analysis","volume":"16","author":"Dur\u00e1n","year":"2021","journal-title":"PLoS One"},{"key":"2024052111014172000_28.3.151.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.5150"},{"key":"2024052111014172000_28.3.151.9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/17407745211005044","article-title":"Us food and drug administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018","volume":"18","author":"Skydel","year":"2021","journal-title":"Clin Trials"},{"key":"2024052111014172000_28.3.151.10","doi-asserted-by":"publisher","DOI":"10.4065\/82.4.518"},{"key":"2024052111014172000_28.3.151.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g3596","article-title":"Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study","volume":"348","author":"Lu","year":"2014","journal-title":"BMJ"},{"key":"2024052111014172000_28.3.151.12","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.456"},{"key":"2024052111014172000_28.3.151.13","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e318245a160"},{"key":"2024052111014172000_28.3.151.14","first-page":"1201","article-title":"Medicare prescription drug plan formulary restrictions after postmarket FDA black box warnings","volume":"25","author":"Solotke","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"2024052111014172000_28.3.151.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1408480"},{"key":"2024052111014172000_28.3.151.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071752","article-title":"Characterization and corroboration of safety signals identified from the US food and drug administration adverse event reporting system, 2008-19: cross sectional study","volume":"379","author":"Dhodapkar","year":"2022","journal-title":"BMJ"},{"key":"2024052111014172000_28.3.151.17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/jamainternmed.2020.0074","article-title":"Integrated drug reviews at the US food and drug administration-legal concerns and knowledge lost","volume":"180","author":"Herder","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2024052111014172000_28.3.151.18","doi-asserted-by":"crossref","first-page":"699063","DOI":"10.3389\/fphar.2021.699063","article-title":"South african regulatory authority: the impact of reliance on the review process leading to improved patient access","volume":"12","author":"Keyter","year":"2021","journal-title":"Front Pharmacol"},{"key":"2024052111014172000_28.3.151.19","doi-asserted-by":"publisher","DOI":"10.1177\/009286150904300314"}],"container-title":["BMJ Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjebm-2022-112005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T18:30:52Z","timestamp":1716316252000},"score":1,"resource":{"primary":{"URL":"https:\/\/ebm.bmj.com\/lookup\/doi\/10.1136\/bmjebm-2022-112005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,5,22]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1136\/bmjebm-2022-112005"],"URL":"https:\/\/doi.org\/10.1136\/bmjebm-2022-112005","relation":{},"ISSN":["2515-446X","2515-4478"],"issn-type":[{"type":"print","value":"2515-446X"},{"type":"electronic","value":"2515-4478"}],"subject":[],"published":{"date-parts":[[2023,3,21]]}}}